Inventiva S.A. (IVA) AI Stock Analysis
IVA AI stock analysis summary
AI ResearchInventiva S.A. (IVA) is a clinical-stage biopharmaceutical company developing oral small molecule therapies. The company generated trailing twelve months revenue of $2.5M with an operating margin of -5337.3%. As of June 30, 2026, it held net cash of $99.4M, while its shares trade at $2.94 following a 1-year return of -39.4%.
- Market cap
- $694.5M
- Revenue (TTM)
- $2.5M
- P/E
- —
- 1Y return
- -39.4% S&P 500 16.8%
- Avg. target
- $15.20 417.0% vs last close
Bull case
- Analysts maintain 11 Strong Buy ratings and 1 Buy rating with a mean price target of $15.20, implying 417.0% upside versus the last close of $2.94.
- The company holds $166.1M in cash and short-term investments with a net cash position of $99.4M as of June 30, 2026.
- EPS growth for the current fiscal year ending December 31, 2026, is estimated at 68.8% to -$0.68.
Bear case
- Revenue fell 51.3% in FY2025 to $4.5M and dropped 76.7% year-over-year in the latest quarter ending June 30, 2026.
- Inventiva generated negative free cash flow of -$101.2M and an operating margin of -2921.0% in FY2025.
- The company's 5-year share count change reached 590.7%, indicating substantial past dilution.
What Inventiva does
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other conditions. Its lead product candidate, Lanifibranor, completed a Phase IIb clinical trial for NASH. Another therapy, Odiparcil, completed a Phase IIa trial for MPS VI. The company also maintains early-stage programs in oncology and collaborates with partners, including AbbVie for autoimmune diseases and Boehringer Ingelheim International GmbH for idiopathic pulmonary fibrosis. Founded in 2011 and based in Daix, France, Inventiva aims to transform patient care across diverse therapeutic areas.
Growth and profitability
Revenue grew from $4.2M in FY2021 to $12.2M in FY2022 and $17.5M in FY2023, before falling 47.4% to $9.2M in FY2024 and falling 51.3% to $4.5M in FY2025. Despite a 5-year revenue CAGR of 64.5% from FY2020 to FY2025, gross margin contracted from 100.0% in FY2024 to 33.7% in FY2025. Net income widened from -$49.6M in FY2021 to -$340.2M in FY2025, reflecting research and development expenses of $83.6M in FY2025. In the trailing twelve months ending June 30, 2026, revenue stood at $2.5M, with quarterly revenue growth falling 76.7% year-over-year and an EPS of -$0.62.
Balance sheet and cash flow
As of June 30, 2026, Inventiva S.A. held $166.1M in cash and short-term investments and $66.6M in total debt, leaving net cash of $99.4M. Its current ratio stood at 3.81, with a debt-to-equity ratio of 1.13 and shareholders' equity of $59.0M. For FY2025, operating cash flow was -$101.0M and free cash flow was -$101.2M, while capital expenditures totaled $237,255. The company's share count increased 590.7% over 5 years.
Valuation and performance
At a last close of $2.94, Inventiva S.A. has a market cap of $694.5M and an enterprise value of $615.5M. The stock trades at a price-to-sales ratio of 282.8x and an EV-to-revenue ratio of 119.9x, compared to the median of its US-listed Healthcare peers of 4.1x price-to-sales. Price-to-book stands at 2.1x. Over the past year, the stock returned -39.4% compared to a 16.8% return for the S&P 500 (SPY), and its 5-year return was -78.1% versus 83.0% for SPY.
What analysts expect
Inventiva S.A. has 11 Strong Buy ratings, 1 Buy rating, and 0 Hold, Sell, or Strong Sell ratings. The mean price target is $15.20, representing an upside of 417.0% from the last close of $2.94. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $5.1M and an EPS of -$0.68. For the next fiscal year, 7 analysts project revenue of $2.2M and an EPS of -$0.75. Over the last 4 quarters, the company delivered 2 EPS beats.
Key risks and what to watch
- Ongoing annual cash burn is substantial, as seen in the -$101.0M operating cash flow in FY2025 against $166.1M in cash and short-term investments as of June 30, 2026.
- Revenue visibility remains weak, with next fiscal year revenue projected by analysts to fall 56.4% to $2.2M.
- Valuation multiples are elevated relative to fundamentals, with price-to-sales at 282.8x compared to the US-listed Healthcare median of 4.1x.
- Market performance has lagged severely, with a 5-year return of -78.1% compared to an 83.0% gain for the S&P 500 (SPY).
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this IVA AI stock analysis
This page is an AI-written research summary of Inventiva S.A. (IVA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: IVA income statement, IVA balance sheet, IVA key metrics, IVA analyst forecast, IVA chart. See the IVA stock overview for the latest quote and news.
IVA AI stock analysis FAQ
What is Inventiva S.A.'s core focus?
Inventiva S.A. is a clinical-stage biopharmaceutical company developing oral small molecule therapies, led by Lanifibranor for NASH and Odiparcil for MPS VI.
Does Inventiva S.A. pay a dividend?
The company does not pay a dividend.
What are analysts forecasting for Inventiva S.A.'s revenue and earnings?
Analysts estimate revenue of $5.1M and an EPS of -$0.68 for the current fiscal year ending December 31, 2026. For the next fiscal year, revenue is projected at $2.2M with an EPS of -$0.75.
What is Inventiva S.A.'s cash and debt position?
As of June 30, 2026, Inventiva S.A. held $166.1M in cash and short-term investments, $66.6M in total debt, and net cash of $99.4M, with a current ratio of 3.81.
How has IVA stock performed compared to the broader market?
IVA shares closed at $2.94 on October 16, 2026, posting a 1-year return of -39.4% and a 5-year return of -78.1%, while the S&P 500 (SPY) returned 16.8% and 83.0% over those respective periods.